

Clinical trial summary (S1900J)

Targeted Treatment for Advanced Non-Small Cell Lung Cancer that has Extra Copies of the *MET* Gene



What is the purpose of this clinical trial?

This study tests treatment for non-small cell lung cancer (NSCLC) that has extra copies of the *MET* gene. Having too many copies of the *MET* gene is called *MET* amplification. It can cause cancer to grow and spread faster.

Targeting the *MET* gene is one approach doctors use to fight this type of rare lung cancer. This study will test a drug called **amivantamab SC**. The drug targets *MET* and helps activate the body's immune system.

Amivantamab SC is given as an injection under the skin. The drug can also be given as an IV infusion through a vein in the arm. The IV form of amivantamab has been approved by the Food and Drug Administration (FDA) to treat some types of advanced NSCLC.

This trial is set up to find out:

- If amivantamab SC can shrink NSCLC that has extra copies of the *MET* gene and lower the chance of it growing or spreading
- What side effects people have from amivantamab SC



Why is this trial important?

Having extra copies of the *MET* gene is just one kind of abnormal change that can happen with the *MET* gene. Previous research has shown that patients with certain *MET* gene changes benefit from treatment using amivantamab SC. But more research is needed to know if the drug can help control cancer with extra *MET* copies. This study is a chance to learn if amivantamab SC can improve lung cancer treatment for more patients.



Who can be in this trial?

This trial is for adults, age 18 or older, with non-small cell lung cancer that is stage 4 or has come back after treatment.

This trial is for people who:

- Have cancer that has extra copies of the *MET* gene
- Have cancer that got worse after previous treatment

This trial is not for people who:

- Already received *MET*-targeted drug treatment (such as tepotinib, capmatinib, or crizotinib)
- Have eye problems that could be affected by the study treatment
- Have serious heart problems

Talk with your doctor to learn more about who can join this study.



What treatments will I get?

All people in this study will receive the study drug amivantamab SC.



How long will I be in the trial?

You may be in the study for up to 3 years. You will continue getting treatment for as long as you benefit from it. You may choose to stop being in the study for any reason at any time. Your doctor may stop your treatment if side effects become too severe or your condition gets worse.

If you stop getting treatment, you will have follow-up visits with the study team until the end of 3 years.

This trial is part of a larger study called Lung-MAP. If your condition gets worse, you may have the option to join another Lung-MAP study.



Are there costs? Will I get paid?

The study drug amivantamab SC is provided free in this study.

Check with your health care provider and insurance provider about what costs will and won't be covered in the study. You will not be paid for joining the study.



Where can I find more information about this trial?

- Talk with your health care provider
- Call the National Cancer Institute at **1-800-4-CANCER**
- Go to ClinicalTrials.gov and search the national clinical trial number: **NCT06116682**
- Go to lung-map.org/patients
- For a list of trial locations, visit swog.org/NCI-S1900J



Key information *This trial is for adults 18 years or older being*

Full trial title: A Phase II Study of amivantamab SC in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

Protocol number: S1900J

NCT number: NCT06116682

Trial sponsor: SWOG Cancer Research Network

Publishing date: July 31, 2024

Thank you!

When you join a clinical trial,
you're moving cancer medicine and patient care forward.